SGRY
Q4 2026 EPS Estimate
$0.09
Nov 9, 2026
Revenue Estimate
$855M
FY2026E EPS$0.45
FY2027E EPS$0.54

Analyst Sentiment

Wall St. Consensus
Buy
19 analysts·Moderate coverage
68
Score
14 Buy (74%)5 Hold (26%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1474%
Hold
526%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$17.00
+22.2%
Consensus
$18.50
+33.0%
Bull
$21.00
+50.9%
12-Month Target Range19 analysts
$17.00$18.50$21.00
Current $13.91Consensus
Current Price
$13.91
Upside to Consensus
$4.59

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+2.69%
EPS+21.81%
FY2028
Rev+4.28%
EPS+27.92%
FY2029
Rev-1.71%
EPS-19.25%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$3.42B$3.51B$3.66B$3.60B
Low$3.40B$3.50B$3.62B$3.47B
High$3.46B$3.53B$3.70B$3.64B
EBITDA Avg$586M$601M$627M$616M
Low$582M$600M$619M$595M
High$593M$605M$633M$624M
EBIT Avg$425M$436M$455M$447M
Low$422M$435M$449M$432M
High$430M$439M$459M$453M
Net Income Avg$55M$82M$87M$71M
Low$50M$52M$84M$68M
High$61M$83M$90M$72M
EPS Avg$0.45$0.54$0.69$0.56
Low$0.39$0.41$0.66$0.53
High$0.48$0.65$0.70$0.57
Analysts (Rev / EPS)8 / 67 / 64 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$855M$906M$814M$858M$865M$928M$889M$934M
Low$854M$905M$805M$848M$855M$916M$879M$922M
High$855M$907M$819M$863M$870M$933M$895M$939M
EBITDA Avg$146M$155M$139M$147M$148M$159M$152M$160M
Low$146M$155M$138M$145M$146M$157M$150M$158M
High$146M$155M$140M$148M$149M$160M$153M$161M
EBIT Avg$106M$113M$101M$107M$107M$115M$110M$116M
Low$106M$112M$100M$105M$106M$114M$109M$115M
High$106M$113M$102M$107M$108M$116M$111M$117M
Net Income Avg$14M$38M$-3M$11M$22M$42M$741,516$18M
Low$10M$37M$-3M$11M$22M$41M$729,864$17M
High$18M$38M$-3M$11M$22M$42M$747,138$18M
EPS Avg$0.11$0.29$-0.02$0.09$0.17$0.33$0.01$0.14
Low$0.07$0.29$-0.02$0.08$0.17$0.32$0.01$0.13
High$0.14$0.29$-0.02$0.09$0.17$0.33$0.01$0.14
Analysts (Rev / EPS)6 / 66 / 53 / 33 / 33 / 33 / 34 / 44 / 4

Earnings Surprises

Recent Analyst Actions

Aug 11, 2026Raymond James
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY), Highlights Improved Cash Conversion
Target:$18.00
+17.3%from $15.34
Aug 11, 2026RBC Capital
Surgery Partners price target lowered to $19 from $20 at RBC Capital
Target:$19.00
+19.1%from $15.95
May 6, 2026Jefferies
Surgery Partners price target raised to $17 from $15 at Jefferies
Target:$17.00
+14.6%from $14.83
Apr 20, 2026Jefferies
Surgery Partners price target lowered to $15 from $16.25 at Jefferies
Target:$15.00
+5.1%from $14.27
Mar 11, 2026US Capital Advisors
UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders
Target:$21.00
+55.6%from $13.50
Mar 4, 2026Jefferies
Surgery Partners (SGRY) PT Lowered to $16.25 at Jefferies
Target:$16.25
+13.9%from $14.27
Mar 4, 2026RBC Capital
Surgery Partners (SGRY) PT Lowered at RBC Capital as 2026 Guide Prompts Selloff
Target:$20.00
+40.7%from $14.21
Mar 3, 2026Jefferies
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results
Target:$30.00
+123.7%from $13.41
Dec 18, 2025Mizuho Securities
Surgery Partners price target lowered to $19 from $22 at Mizuho
Target:$19.00
+20.3%from $15.80
Nov 21, 2025Barclays
Surgery Partners price target lowered to $18 from $24 at Barclays
Target:$18.00
+17.6%from $15.30
Nov 17, 2025Mizuho Securities
Surgery Partners price target lowered to $22 from $28 at Mizuho
Target:$22.00
+44.7%from $15.20
Nov 13, 2024Jefferies
Surgery Partners (SGRY) PT Lowered to $40 at Jefferies
Target:$40.00
+34.5%from $29.74
Nov 13, 2024Barclays
Surgery Partners (SGRY) PT Lowered to $31 at Barclays
Target:$31.00
+4.2%from $29.74
Oct 14, 2024UBS
UBS Starts Surgery Partners (SGRY) at Buy
Target:$38.00
+24.8%from $30.46
Jun 28, 2024Macquarie
Macquarie Starts Surgery Partners (SGRY) at Outperform
Target:$31.00
+27.5%from $24.32
May 4, 2022Citigroup
Citigroup Maintains Buy on Surgery Partners, Raises Price Target to $64
Target:$64.00
+19.4%from $53.62
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.